On May 23, 2024 Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), reported that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024 (Press release, Heidelberg Pharma, MAY 23, 2024, View Source [SID1234643599]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Heidelberg Pharma is an ADC specialist, developing innovative drugs based on its proprietary ADC toolbox for the targeted and highly effective treatment of cancer. Its lead Amanitin-based ADC product candidate, HDP-101, targeting relapsed or refractory multiple myeloma has recently received Orphan Drug Designation (ODD) and is currently advancing in a Phase I/IIa clinical trial, demonstrating first signs of clinical efficacy. The Company is also rapidly expanding its therapeutic product pipeline with a further four programs across a variety of malignant hematologic and solid tumors.
10th Annual Oncology Innovation Forum
Date & location: 31 May 2024, Chicago, Illinois, USA
Panel: Investing in NextGen ADCs
Date: 31 May, 10:45 am CDT
Panellist: Professor Andreas Pahl, Chief Executive Officer
Presentation title: Company presentation
Date: 31 May, 02:00 pm CDT
Presenter: Professor Andreas Pahl, Chief Executive Officer
Professor Pahl will be available for one-on-one meetings, which can be arranged via the online conference system.
ASCO Annual Meeting
Date & location: 31 May–4 June 2024, Chicago, Illinois, USA
Attending: Professor Andreas Pahl, Chief Executive Officer & Dr. András Strassz, Chief Medical Officer
Professor Pahl and Dr. Strassz will be available for meetings.
BIO International Convention
Date & location: 3–6 June 2024, San Diego, California, USA
Attending: Dr. George Badescu, Chief Business Officer & Dr. Artjom Wischnjow, Associate Director Business Development
Dr. Badescu and Dr. Wischnjow will be available for one-on-one meetings, which can be arranged via the online conference system.
Jefferies Global Healthcare Conference
Date & location: 4–6 June 2024, New York, USA
Attending: Professor Andreas Pahl, Chief Executive Officer & Dr. George Badescu, Chief Business Officer
Professor Pahl and Dr. Badescu will be available for one-on-one meetings, which can be arranged via the online conference system.